One of the mysteries of the English language finally explained.
noun & adjective
- ‘the advent of biogenerics could cause biotech companies to withhold more information about their products’another term for biosimilar‘biogeneric versions of off-patent medicines’
- ‘If competing firms are permitted to manufacture them, biogeneric versions of the off-patent medicines could command $5 billion next year.’
- ‘Rules in the U.S. are still unclear, making it difficult for companies to win approval to market biogenerics there.’
- ‘"You get one crack at it," said Robert Coughlin, president of the Massachusetts Biotechnology Council, speaking of the task of drawing up a licensing system for "biogenerics."’
- ‘The FDA has been trying to get its regulatory head around the issue of biogeneric equivalency, but it isn't easy.’
- ‘At the same time that Amgen is getting ready to launch its own biosimilars, Amgen and other biotechs are campaigning state governments to make it harder to substitute a biogeneric for a brand.’
- ‘Large growth is expected to come on the back of increased partnering activity, transition to product-driven models, growth in the biogenerics market and government initiatives to encourage investment and expansion.’
- ‘Some biotech drug manufacturers are lobbying state legislators to restrict access to biosimilar (or biogeneric) versions of expensive brand medications, the Pharmaceutical Care Management Association (PCMA) said today.’
- ‘"I feel that a value of $1 billion is reasonable for a proven technological platform in the generics sector, especially in biogenerics, which currently very much interests the major firms."’
- ‘CCPM coalition members urged Congress to fix or drop the current biogenerics provision.’
1990s: from bio- + generic.
Top tips for CV writingRead more
In this article we explore how to impress employers with a spot-on CV.